Ironomycin

Overview

Ironomycin is a derivative of Salinomycin ( HY-15597 ). Ironomycin exhibits selective inhibitory activity against mantle cell lymphoma (MCL) cells. Ironomycin blocks the cell cycle and induces apoptosis and ferroptosis . Ironomycin induces double-strand DNA breaks and activates the unfolded protein response (UPR), particularly the IRE1α signaling pathway accumulation. The combination of Ironomycin with Ibrutinib ( HY-10997 ) shows a synergistic effect. Ironomycin can be used for the study of MCL.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Others | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Drug Derivative | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > IRE1 | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-150280
• CAS No.: 1884647-72-6
• Molecular Formula: C45H73NO10
• Molecular Weight: 788.06
• Purity: 99.85%
• Storage: -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (3.17 mM); Clear solution
• Availability: In-stock

Source

Original product source